Montréal medical-software company whose ETNA-MS app records eye movements on an iPad and runs a locked machine-learning model in the cloud to score disability and cognition in people with multiple sclerosis.
Canadian innovation builds a brighter tomorrow.
Montréal medical-software company whose ETNA-MS app records eye movements on an iPad and runs a locked machine-learning model in the cloud to score disability and cognition in people with multiple sclerosis.
Operates as 10032506 Canada Inc., federal corporation 1003250-6, status Active, registered office on avenue de l'Épée in Montréal — the address on its contact page. ised-isde.canada.ca
Health Canada cleared ETNA-MS in March 2024 as a Class II software medical device producing an EDSS disability score from eye-movement data for multiple sclerosis. newswire.ca
Signed a multi-year commercial framework agreement with Novartis Pharmaceuticals Canada in September 2023, including a pan-Canadian pilot of up to 15 sites. newswire.ca
Received FDA Breakthrough Device designation in May 2022 for its tablet-based eye-tracking technology in multiple sclerosis. The company's site still describes FDA clearance as pending. newswire.ca
Products Innodem Neurosciences publishes on its own site. Each card links to the page it was taken from.
Software as a medical device
Company describes an iPad Pro app recording oculomotor tasks, with ETNA-Cloud running a clinically validated and locked machine-learning model to output EDSS and SDMT scores for tracking multiple sclerosis progression and cognition.
Learn moreEye-tracking communication app
Company describes an eye-tracking app that lets voiceless intensive-care patients communicate using only their eye movements.
Learn moreAnnounced rounds only, newest first. Undisclosed amounts are shown as undisclosed.
Jan 19, 2021
Investors: Morningside Ventures
Publicly announced partnerships.
Multi-year commercial framework agreement signed September 2023 to support ETNA, including a pan-Canadian pilot of up to 15 sites. No amount was disclosed.
Health Canada cleared ETNA-MS, a Class II software medical device that uses machine learning on eye-movement data captured on an iPad Pro to produce an EDSS score for multiple sclerosis.
Innodem and Novartis Pharmaceuticals Canada signed a multimillion, multi-year agreement supporting ETNA, including a pan-Canadian pilot of up to 15 sites pending regulatory clearance.
The FDA granted Breakthrough Device designation to Innodem's tablet-based eye-tracking technology for multiple sclerosis.
Innodem closed a Series A led by Morningside Ventures to develop and commercialise its eye-tracking biomarker technology.
Sourced from the company's own pages or announcements.
Étienne de Villers-Sidani
Main Founder, Chief Executive Officer and Chief Scientific Officer
Yves Desgagné
Co-founder and Chief Technology Officer
Marc Reeves
Co-founder and Chief Business Officer
Terms the company uses about its own work.
Other companies in Digital Health & HealthTech.
Discover companies, track funding, explore career opportunities and stay informed about Canada’s growing tech ecosystem.